Latest News and Press Releases

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy...

Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK)...

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS

Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity

–  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a...

Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain The PP353 clinical trial met the...

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax